In the battle against B-cell cancers, drugs that target the enzyme Bruton tyrosine kinase (BTK) have transformed treatment. Before the first BTK inhibitor, ibrutinib, came on the market in 2013, ...
Covalent inhibitors are a specialized class of small molecules designed to form chemical bonds with their target proteins, often resulting in prolonged target engagement and enhanced potency. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback